KRAS and lung carcinoma: We revealed that KRASG12C inhibitors enhance the formation of primary cilia and Hh signaling, and that inhibition of Hh signaling blocks re-expression of KRAS and reactivation of ERK in lung cancer cells treated with a KRASG12C inhibitor.